Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

26.32USD
12:59pm EST
Change (% chg)

$-0.26 (-0.98%)
Prev Close
$26.58
Open
$26.69
Day's High
$26.69
Day's Low
$26.14
Volume
220,091
Avg. Vol
942,026
52-wk High
$32.49
52-wk Low
$14.23

Select another date:

Wed, Nov 1 2017

BRIEF-Exelixis reports Q3 earnings per share $0.26

* Exelixis announces third quarter 2017 financial results and provides corporate update

Exelixis drug improves overall survival in liver cancer patients

Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company's shares soaring 31 percent.

UPDATE 3-Exelixis drug improves overall survival in liver cancer patients

* Shares jump 31 pct (Adds details, company comment, updates shares))

BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial

* Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

Exelixis cancer drug meets key goal in late-stage trial

Oct 16 Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer.

BRIEF-Exelixis to receive milestone payment from Bristol-Myers Squibb

* Exelixis to receive milestone payment from Bristol-Myers Squibb for submission of clinical trial authorization for RORγt inverse agonist program

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer

* Exelixis submits U.S. Supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer Source text for Eikon: Further company coverage:

BRIEF-Exelixis announces settlement of dispute with Genentech

* Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib

BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial

* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Select another date: